We are live on ! Find out more
SWTX

SpringWorks Therapeutics
SWTX

Delisted

SWTX was delisted on the 30th of June, 2025.

Back to rankings

57 hedge funds and large institutions have $1.23B invested in SpringWorks Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

81% more capital invested

Capital invested by funds: $681M → $1.23B (+$552M)

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

30% more funds holding

Funds holding: 44 → 57 (+13)

2.01% more ownership

Funds ownership: 72.34% → 74.35% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
57
Holders Change
+13
Holders Change %
+29.55%
% of All Funds
1.12%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
26
Increased
14
Reduced
10
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$7.48M
3
BI
BVF Inc
California
+$5.5M
4
DCM
Driehaus Capital Management
Illinois
+$5.29M
5
State Street
State Street
Massachusetts
+$3.4M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$9.31M
2
Citadel Advisors
Citadel Advisors
Florida
-$9.2M
3
DM
Deerfield Management
New York
-$6.15M
4
LCM
Laurion Capital Management
New York
-$3.38M
5
SFM
Sphera Funds Management
Israel
-$2.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$90K -$94 -4 -0.2%
Citigroup
52
Citigroup
New York
$81K +$49K +2,094 New
Bank of America
53
Bank of America
North Carolina
$64K +$38.8K +1,658 New
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$50K +$30.7K +1,312 New
Wells Fargo
55
Wells Fargo
California
$48K +$19.9K +851 +213%
AIP
56
Ameritas Investment Partners
Nebraska
$35K +$21K +897 New
WCA
57
Windsor Creek Advisors
Vermont
$311 +$189K +8,068 New
MIM
58
Monashee Investment Management
Massachusetts
– -$1.79M -82,803 Closed
Wellington Management Group
59
Wellington Management Group
Massachusetts
– -$1.53M -70,577 Closed
Goldman Sachs
60
Goldman Sachs
New York
– -$1.1M -50,760 Closed
MWNA
61
Marshall Wace North America
New York
– -$775K -35,761 Closed
CS
62
Credit Suisse
Switzerland
– -$592K -27,319 Closed
DIM
63
DC Investments Management
Virginia
– -$575K -26,513 Closed
WAM
64
Weiss Asset Management
Massachusetts
– -$373K -17,194 Closed
Susquehanna International Group
65
Susquehanna International Group
Pennsylvania
– -$312K -14,392 Closed
Jane Street
66
Jane Street
New York
– -$307K -14,142 Closed
DKCM
67
Davidson Kempner Capital Management
New York
– -$271K -12,500 Closed
Tudor Investment Corp
68
Tudor Investment Corp
Connecticut
– -$223K -10,276 Closed
TRCT
69
Tower Research Capital (TRC)
New York
– -$22K -1,014 Closed
CCA
70
Catalyst Capital Advisors
New York
– -$6K -260 Closed
1 2
3

SWTX Hedge Fund Activity: Q4 2019 in Review

57 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2019, worth a combined $1.23B — up 81% from $681M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new SWTX positions and 13 closed out — a net gain of 13 holders — while 14 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $12.6M. The largest seller was Millennium Management, cutting an estimated $9.31M.

  • 57 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2019, up from 44 in Q3 2019.
  • Funds reported $1.23B of SpringWorks Therapeutics stock for Q4 2019, up 81% quarter-over-quarter.
  • 26 funds opened new SpringWorks Therapeutics positions in Q4 2019 and 13 closed out, a net change of +13 holders.
  • The largest SpringWorks Therapeutics buyer in Q4 2019 was BlackRock, an estimated $12.6M added.
  • The largest SpringWorks Therapeutics seller in Q4 2019 was Millennium Management, an estimated $9.31M sold.

Based on aggregated 13F filings for Q4 2019.